Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imagion BiosystemsASX:IBX 3-Year RORE % is -84.49 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 92.04% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Imagion Biosystems's 3-Year RORE % for the quarter that ended in Dec. 2025 was -84.49%.
The industry rank for Imagion Biosystems's 3-Year RORE % or its related term are showing as below:
ASX:IBX's 3-Year RORE % is ranked worse than 92.04% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -7.98
vs ASX:IBX: -84.49
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Imagion Biosystems 3-Year RORE % Related Terms
Imagion Biosystems 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IBX vs TMO, DHR, IDXX: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Imagion Biosystems (ASX:IBX) has a 3-Year RORE % of -84.49 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #185 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 92%.
Is Imagion Biosystems' 3-Year RORE % too high?
Imagion Biosystems' current 3-Year RORE % is -84.49. Based on the distribution chart, Imagion Biosystems ranks #185 out of 201 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #185 out of 201 companies for 3-Year RORE %. This places Imagion Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Imagion Biosystems and its competitors. Imagion Biosystems's current 3-Year RORE % is -84.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (ASX:IBX) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.13, compared to a current price of A$0.01 — trading 99% below its estimated fair value. The current 3-Year RORE % is -84.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Imagion Biosystems (ASX:IBX), the current 3-Year RORE % is -84.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IBX has been successfully added to your 
